Affluent Medical S.A.
AFME.PA · PAR
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.09 | 0.48 | 0.04 |
| FCF Yield | -14.23% | -7.50% | -6.53% | -22.81% |
| EV / EBITDA | -13.18 | -8.26 | -10.33 | -7.61 |
| Quality | ||||
| ROIC | -10.37% | -19.68% | -15.73% | -7.11% |
| Gross Margin | -80.21% | -66.57% | -96.69% | -99.49% |
| Cash Conversion Ratio | 0.72 | 1.42 | 0.41 | 0.46 |
| Growth | ||||
| Revenue 3-Year CAGR | 48.30% | 38.63% | 6.80% | 8.76% |
| Free Cash Flow Growth | -95.10% | -5.47% | 57.29% | -78.72% |
| Safety | ||||
| Net Debt / EBITDA | -2.92 | -2.01 | -2.23 | -1.72 |
| Interest Coverage | 12.34 | -12.93 | 0.00 | -12.96 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 40.74 | 275.30 | 239.35 | 555.51 |